Eyewire Today | Newest Articles http://eyewiretoday.com/ Newest Articles en-us Sun, 18 Mar 2018 23:04:41 GMT Sun, 18 Mar 2018 23:04:41 GMT Eyetube.net In Diabetic Peripheral Neuropathy, Iron Overload is a Risk Factor http://eyewiretoday.com/view.asp?url=20140314-in_diabetic_peripheral_neuropathy_iron_overload_is_a_risk_factor Iron overload can lead to cytotoxicity, and it is a risk factor for diabetic peripheral neuropathy. However, the underlying mechanism remains unclear. Prof. Shi Zhao and team conjectured that iron overload-induced neurotoxicity might be associated with oxidative stress and the NF-E2-related factor 2 (Nrf2)/ARE signaling pathway. As an in vitro cellular model of diabetic peripheral neuropathy, PC12 cells exposed to high glucose concentration were used in this study. Fri, 14 Mar 2014 14:05:00 GMT Gut Microbiota Networks May Influence Autoimmune Processes in Yype 1 Diabetes http://eyewiretoday.com/view.asp?url=20140314-gut_microbiota_networks_may_influence_autoimmune_processes_in_yype_1_diabetes The interactions of the gut microbiota in children with typical diabetes autoantibodies differ from that in healthy children. The fact that these differences already exist before antibodies are detectable in the blood adds to the growing evidence that microbial DNA, the so-called microbiome, may be involved in the development of autoimmune processes. Scientists from the Helmholtz Zentrum Mnchen have published their findings in the specialist journal Diabetes. Fri, 14 Mar 2014 14:04:00 GMT Low-Dose Doxycycline May Slow Diabetic Retinopathy http://eyewiretoday.com/view.asp?url=20140314-low-dose_doxycycline_may_slow_diabetic_retinopathy Low-dose doxycycline could slow the progression of diabetic retinopathy (DR), according to a small proof-of concept study by a group of researchers in the United States and Denmark, published online March 6 in JAMA Ophthalmology. "To our knowledge, this is the first observation suggesting a link between a low-dose oral anti-inflammatory agent and subclinical improvement in inner retinal function," write Ingrid U. Scott, MD, MPH, from the Penn State Hershey Eye Center and the Department of Public... Fri, 14 Mar 2014 14:02:00 GMT Mortality Risk High in Diabetic Cancer Patients Using Insulin http://eyewiretoday.com/view.asp?url=20140314-mortality_risk_high_in_diabetic_cancer_patients_using_insulin Cancer patients with pre-existing diabetes have a greater risk for death compared with nondiabetics, with the highest mortality observed in those using insulin. For all cancers combined, the authors of a large Danish study found that patients who had diabetes for 2 years, and who had been treated with insulin at the time of cancer diagnosis, had a mortality rate that was about 4 times higher than that of nondiabetics. The higher risk was observed 1 year after being diagnosed with cancer. Fri, 14 Mar 2014 14:02:00 GMT Huge Burden of Foot Ulcers Doubles Diabetes Costs in US http://eyewiretoday.com/view.asp?url=20140314-huge_burden_of_foot_ulcers_doubles_diabetes_costs_in_us Diabetic foot ulcers impose a substantial burden on public and private payers in the United States, doubling care costs per patient compared with diabetic patients without foot ulcers. Ulcer care adds around US $9 billion to $13 billion to the direct yearly costs associated with diabetes itself, according to a new study examining the annual, per-patient burden of diabetic foot ulcers, published in the March issue of Diabetes Care. Fri, 14 Mar 2014 14:01:00 GMT Reduced Insulin Dose After Exercise Helps Avert Hypoglycemia http://eyewiretoday.com/view.asp?url=20130401-reduced_insulin_dose_after_exercise_helps_avert_hypoglycemia A small study of patients with type 1 diabetes has shown the merits of greatly reducing the dose of insulin taken after as well as before exercise, to avoid hypoglycemia. Patients who took a 25% dose of insulin before running on a treadmill for 45 minutes and then took a 50% dose of insulin an hour later were protected from hypoglycemia during or soon after exercise. They were, however, still at risk for a dangerous drop in blood glucose later that evening. Mon, 1 Apr 2013 14:35:00 GMT EU Will Study Risks of Incretin Mimetics for Diabetes http://eyewiretoday.com/view.asp?url=20130401-eu_will_study_risks_of_incretin_mimetics_for_diabetes Taking a cue from their US counterparts, European drug regulators announced Wednesday that they will investigate the findings of a recent study in the journal Diabetes suggesting that incretin mimetic drugs for type 2 diabetes increase the risk for pancreatitis and precancerous cellular changes called pancreatic duct metaplasia. On March 14, the US Food and Drug Administration (FDA) announced that it will review the same research results on incretin mimetics. At that time, the study was unpublis... Mon, 1 Apr 2013 14:34:00 GMT Heart-Smart Diabetes Drugs: Pipe Dream or Possibility? http://eyewiretoday.com/view.asp?url=20130401-heart-smart_diabetes_drugs_pipe_dream_or_possibility? Everyone remembers rosiglitazone (Avandia, GlaxoSmithKline), a diabetes drug finally withdrawn in Europe and severely restricted in the United States in 2010 after it emerged that it could increase the risk for heart attack and cardiovascular death. Debate about rosiglitazone had rumbled on for years, and prior to its demise, the US Food and Drug Administration (FDA) had already decreed in 2008 that, going forward, new type 2 diabetes drugs should be subject to more stringent clinical trials, to... Mon, 1 Apr 2013 14:33:00 GMT Popular Diabetes Drugs May Cause Abnormal Pancreatic Growth In Humans http://eyewiretoday.com/view.asp?url=20130401-popular_diabetes_drugs_may_cause_abnormal_pancreatic_growth_in_humans Individuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine tumors, according to a new study by researchers from UCLA and the University of Florida. Their findings were published online in the journal Diabetes. The researchers, from the Larry L. Hillblom Islet Research Center at UCLA and the Diabetes Center at the University of Florida, found tha... Mon, 1 Apr 2013 14:32:00 GMT JJ Wins U.S. Approval for First-in-Class Diabetes Drug http://eyewiretoday.com/view.asp?url=20130401-jj_wins_us_approval_for_first-in-class_diabetes_drug Johnson & Johnson (JNJ), the worlds largest seller of health-care products, won approval for the first in a new family of diabetes drugs, giving them the edge against rivals developing similar medicines. The U.S. Food and Drug Administration cleared the drug, known as canagliflozin, to treat adults with Type 2 diabetes, the agency said yesterday in a statement. It may generate $800 million in peak sales, Tony Butler, an analyst at Barclays Plc in New York, said in a telephone interview. Mon, 1 Apr 2013 14:31:00 GMT HbA1c Variability Linked to Nephropathy in Type 2 Diabetes http://eyewiretoday.com/view.asp?url=20130325-hba1c_variability_linked_to_nephropathy_in_type_2_diabetes Fluctuations in glycated hemoglobin (HbA1c) are correlated with the development of nephropathy, but not retinopathy, in patients with type 2 diabetes, according to a new study published online March 14 in Diabetes Care. Recent research has suggested that HbA1c variability is an independent risk factor for the development of diabetic retinopathy and nephropathy in people with type 1 diabetes, as well as microalbuminuria in patients with type 2 diabetes, write Giuseppe Penno, MD, from the Universi... Mon, 25 Mar 2013 14:14:00 GMT Millions on Verge of Diabetes Don't Know It: CDC http://eyewiretoday.com/view.asp?url=20130325-millions_on_verge_of_diabetes_dont_know_it_cdc Only 11 percent of the estimated 79 million Americans who are at risk for diabetes know they are at risk, federal health officials reported Thursday. The condition, known as prediabetes, describes higher-than-normal blood sugar levels that put people in danger of developing diabetes, according to the U.S. Centers for Disease Control and Prevention. Mon, 25 Mar 2013 14:13:00 GMT Hormone Combination Shows Promise In The Treatment Of Obesity And Diabetes http://eyewiretoday.com/view.asp?url=20130325-hormone_combination_shows_promise_in_the_treatment_of_obesity_and_diabetes A new treatment combining two hormones can reduce appetite, according to new research presented at the Society for Endocrinology annual conference in Harrogate, UK. This early study from an internationally-renowned team at Imperial College London provides 'first in man' evidence that a combined therapy using the hormones glucagon and glucagon-like peptide 1 (GLP-1) may form the basis for a new treatment for obesity and diabetes in the future. Mon, 25 Mar 2013 14:09:00 GMT Marker May Show Kidney Disease in Diabetics http://eyewiretoday.com/view.asp?url=20130325-marker_may_show_kidney_disease_in_diabetics High levels of certain inflammatory markers may foretell of the development of macroalbuminuria in patients with type 1 diabetes, researchers found. In an analysis of data from a prospective study, higher baseline levels of soluble E-selectin and soluble tumor necrosis factor receptors (sTNFR) -1 and sTNFR-2 were associated with an increased risk of developing macroalbuminuria over about 6 years, Maria Lopes-Virella, MD, PhD, of the Medical University of South Carolina, and colleagues reported o... Mon, 25 Mar 2013 14:07:00 GMT Provider Switch Tied to Worse Glycemic Control http://eyewiretoday.com/view.asp?url=20130325-provider_switch_tied_to_worse_glycemic_control For patients diagnosed with type 1 diabetes during adolescence, the transition to adult diabetes care can be associated with poor glycemic control, researchers found. When followed up in early adulthood, patients who had transitioned to adult care were about 2.5 times more likely to have a hemoglobin A1c of 9% or higher compared with those who had continued receiving care from their pediatric provider (odds ratio 2.46, 95% CI 1.09 to 5.55), according to Debra Lotstein, MD, MPH, of the University... Mon, 25 Mar 2013 14:06:00 GMT FDA to Probe New Diabetes Drugs, Precancerous Changes in Pancreas http://eyewiretoday.com/view.asp?url=20130315-fda_to_probe_new_diabetes_drugs_precancerous_changes_in_pancreas The Food and Drug Administration has announced that it will investigate whether a new class of Type 2 diabetes drugs sometimes called the "gliptins" may increase patients' risk of developing precancerous changes in the pancreas, as well as of developing acute pancreatitis. Fri, 15 Mar 2013 14:35:00 GMT High-Pressure Diving Tank Could Aid Stem Cell Therapies for Type 2 Diabetes http://eyewiretoday.com/view.asp?url=20130315-high-pressure_diving_tank_could_aid_stem_cell_therapies_for_type_2_diabetes Scientists in the US believe so-called hyperbaric oxygen therapy combined with stem cell treatment could hold the key to reversing type 2 diabetes. Hyperbaric oxygen therapy involves a patient sitting in a pressurised diving chamber. It is normally used for helping divers who have surfaced too quickly and have bubbles of nitrogen in the blood, but can also help speed up healing of wounds. Fri, 15 Mar 2013 14:32:00 GMT Glucose Control Put In Double Jeopardy By Polycystic Ovary Syndrome http://eyewiretoday.com/view.asp?url=20130315-glucose_control_put_in_double_jeopardy_by_polycystic_ovary_syndrome Polycystic ovary syndrome, a condition affecting about 10 percent of women and characterized by excess male hormone and increased risk of diabetes and heart disease, appears to cause a sort of double jeopardy for those struggling the hardest to control blood sugar levels, researchers report. Fri, 15 Mar 2013 14:29:00 GMT No Clear Evidence That Decline In HRT Use Linked To Fall In Breast Cancer http://eyewiretoday.com/view.asp?url=20130315-no_clear_evidence_that_decline_in_hrt_use_linked_to_fall_in_breast_cancer There is no clear evidence that the decline in the use of hormone replacement therapy (HRT) is linked to a reported fall in the numbers of new cases of breast cancer, as has been claimed, suggests a study in the Journal of Family Planning and Reproductive Health Care. Fri, 15 Mar 2013 14:28:00 GMT Alogliptin Used Alone or With Other Medications is Effective for Blood Sugar Control http://eyewiretoday.com/view.asp?url=20130314-alogliptin_used_alone_or_with_other_medications_is_effective_for_blood_sugar_control While several medications are already on the market to treat diabetes, not all patients have the desired control over their blood sugar levels. Alogliptinmay offera fresh option. In January, the FDA approved the medication alogliptin (brand name Nesina) for treatment of adults with type 2 diabetes. Thu, 14 Mar 2013 13:48:00 GMT Resistance Training Benefits Type 2 Diabetics http://eyewiretoday.com/view.asp?url=20130314-resistance_training_benefits_type_2_diabetics Improvements in body composition with progressive resistance exercise led to better glucose control and less insulin resistance among older type 2 diabetes patients, but the same phenomenon was not seen with low-resistance "sham" exercise, researchers found. The results, from the Graded Resistance Exercise and Type 2 Diabetes in Older Adults (GREAT2DO) study were published online March 8 in Diabetes Care by Yorgi Mavros, a PhD candidate and postgraduate teaching fellow at the University of Sydne... Thu, 14 Mar 2013 13:46:00 GMT Modified Insulin Regimen Helpful in Hospitalized Diabetics http://eyewiretoday.com/view.asp?url=20130314-modified_insulin_regimen_helpful_in_hospitalized_diabetics In hospitalized type 2 diabetics, a single basal dose of insulin plus correction before meals if needed is a good alternative to a basal bolus approach, researchers say. Glycemic control was similar whether patients took a single basal dose and correction doses of rapid-acting insulin before meals, or basal insulin once daily and rapid-acting insulin before each meal plus correction doses of rapid-acting insulin before meals if needed. Thu, 14 Mar 2013 13:45:00 GMT Women with Gestational Diabetes at Much Greater Risk of Type 2 Diabetes http://eyewiretoday.com/view.asp?url=20130312-women_with_gestational_diabetes_at_much_greater_risk_of_type_2_diabetes New research suggests that women who develop gestational diabetes during pregnancy are significantly more likely to be diagnosed with type 2 diabetes in the future. The study, led by Soo Heon Kwak of Seoul National University Hospital, South Korea, followed 843 women in Seoul who were diagnosed with gestational diabetes between 1996 and 2003, making it one of the largest of its kind to study gestational diabetes in Asian women. Tue, 12 Mar 2013 14:32:00 GMT Certain Diabetes Medications May Lower Heart Failure Risk http://eyewiretoday.com/view.asp?url=20130312-certain_diabetes_medications_may_lower_heart_failure_risk A newer class of diabetes drugs may offer an extra benefit: A new study suggests these medications lower the odds of suffering heart failure. Researchers from Henry Ford Hospital in Detroit found that patients taking so-called GLP-1 drugs -- including brand-name medications such as Byetta, Januvia and Victoza -- were more than 40 percent less likely to be hospitalized for heart failure than patients prescribed other blood sugar-lowering medications. GLP-1 diabetes drugs have been in use for only... Tue, 12 Mar 2013 14:30:00 GMT Anti-Angina Tx Offers Relief in Diabetes http://eyewiretoday.com/view.asp?url=20130312-anti-angina_tx_offers_relief_in_diabetes The anti-angina drug ranolazine successfully prevented chest pain in previously treated patients with type 2 diabetes and chronic stable angina, researchers reported here. The use of ranolazine (Ranexa) in diabetic patients with documented coronary artery disease and stable angina resulted in a significant reduction in average weekly chest pain episodes compared with placebo at 8 weeks (3.8 versus 4.3, P=0.008), reported Mikhail Kosiborod, MD, of the University of Missouri's St. Luke's Mid Ameri... Tue, 12 Mar 2013 14:28:00 GMT